桂林三金药业股份有限公司 第八届董事会第十六次会议决议公告 证券代码：002275 证券简称：桂林三金 公告编号：2025-034 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 桂林三金药业股份有限公司（以下简称公司）于2025年12月4日以书面和电 子邮件方式向董事和监事发出第八届董事会第十六次会议通知，会议于2025年12 月9日在广西壮族自治区桂林市临桂区人民南路9号公司会议室举行。本次会议应 出席会议的董事9人，实际出席会议的董事9人。会议由公司董事长邹洵先生主持， 公司全体监事、高级管理人员列席了会议。会议召开程序符合《公司法》和《公 司章程》的有关规定。 二、董事会会议审议情况 1.审议通过了《关于修订<公司章程>的议案》（同意票9票，反对票0票，弃 权票0票）。 为进一步完善公司法人治理结构、提升公司规范运作水平，根据《中华人民 共和国公司法（2023年修订）》、中国证监会《关于新<公司法>配套制度规则实 施相关过渡期安排》《上市公司章程指引（2025年修订）》以及《深圳证券交易 所股票上市规则》等法律法规、规范性文件的 ...

业绩与分红双优是企业发展的硬核体现。2024年桂林三金营收稳步增长，净利润同比显著上扬23.79%，"十四 五"期间整体营收保持稳健增长态势。股东回报方面，桂林三金一直以来致力于为广大投资者创造良好、稳定的投 资回报，上市以来持续实施现金分红政策。随着桂林三金披露2025年三季度分红方案，公司已连续四年实现一年 两次分红。 证券时报记者 康殷 作为深耕中药领域的"中华老字号"，桂林三金在"十四五"期间锚定高质量发展方向，以业绩增长筑牢根基，以创新 突破激活动能，在业绩、分红、技术创新等方面交出了一份亮眼答卷，彰显上市公司责任与担当。 精准布局未来赛道上，桂林三金全资子公司宝船生物，专注于肿瘤自免性疾病药物的创新研发，已获得6个临床批 件。其中BC006单抗注射液已结束I期临床试验，即将进入Ⅲ期临床阶段，正积极推动成果转化。CDMO方面，全 资子公司白帆生物，聚焦大分子生物药方面的研发与生产。 凭借多元发展成果，"十四五"期间，桂林三金的两个相关科研项目分别获2022年度、2023年度广西科技进步奖二 等奖，彰显了企业强劲的科研创新实力。如今，桂林三金正以"一体两翼"战略为引领，持续攻克中药关键技术， 以新质生 ...

证券日报网讯 12月2日，桂林三金在互动平台回答投资者提问时表示，截至2025年11月28日股东总户数 为20244户。 （文章来源：证券日报） ...

Core Viewpoint - Guilin Sanjin (002275.SZ) has confirmed that its products, Sanjin Pian and Xigua Shuang, are sold in various overseas markets, including Serbia in Eastern Europe, the United States and Canada in North America, Australia in Oceania, and most countries in Southeast Asia, with no sales currently in EU countries [1] Group 1 - The company has a diverse international market presence for its products [1] - Specific markets mentioned include Eastern Europe, North America, Oceania, and Southeast Asia [1] - There is currently no distribution of products in EU countries [1]

Group 1 - The company, Guilin Sanjin, has products sold in 17 countries, including markets in Eastern Europe, North America, Oceania, and Southeast Asia [2] - The company's products, Sanjin tablets and Watermelon Frost, are not currently sold in EU countries [2]

Core Insights - Guilin Sanjin (002275) reported that as of November 10, 2025, the total number of shareholders is 21,601 [1] Company Summary - The company has engaged with investors through an interactive platform, providing updates on shareholder numbers [1]

Core Viewpoint - Guilin Sanjin (002275) has stated that the company currently does not have any health food products related to the concept of "medicinal food homology" [1] Company Summary - Guilin Sanjin responded to investor inquiries on November 11, clarifying the absence of health food products in their portfolio [1]

Group 1 - The core viewpoint of the articles highlights the recognition of seven listed companies in Guangxi for their high-quality information disclosure, achieving the highest rating of A-level, which represents a significant increase from the previous year [1] - The seven companies that received the A-level rating include Liugong, Beibu Gulf Port, Guohai Securities, Guilin Sanjin, Guiguan Electric Power, Liuyao Co., and Huayuan Co., with Guilin Sanjin achieving this rating for 13 consecutive years [1] - The improvement in information disclosure quality is seen as a benchmark for Guangxi's capital market, emphasizing the importance of transparency and compliance in fostering investor trust [1] Group 2 - The China Listed Companies Association recently announced the results of the 2025 internal control best practice case collection, with two companies from Guangxi recognized for their exemplary practices [2] - Guangxi Fenglin Wood Industry Group's submission on the intelligent internal control system based on "Beidou + Big Data + AI" was selected as a best practice case, while Beibu Gulf Port's submission on internal control for efficient operations was recognized as an excellent case [2] - The initiative aims to enhance corporate compliance and risk prevention, contributing to the establishment of a "Chinese model" for internal control practices [2]

Group 1 - Guilin Sanjin's subsidiary, Hunan Sanjin, produces Yuye Jiedu Granules, which are effective for clearing heat and detoxifying, suitable for treating symptoms like cough, sore throat, and preventing heatstroke [2] - The company also offers Sanjin Cold Relief Granules, which are used for wind-cold colds, alleviating symptoms such as headache, fever, and nasal discharge [2] - The effectiveness of these products against influenza virus is suggested to be evaluated on an individual basis, recommending consultation with a physician or pharmacist [2]

Core Viewpoint - Guilin Sanjin (002275.SZ) is nearing the completion of Phase I clinical trials for its product BC006 monoclonal antibody injection [1] Company Summary - The company has announced on its investor interaction platform that the BC006 monoclonal antibody injection project is about to finish its Phase I clinical trials [1]